246 related articles for article (PubMed ID: 30958398)
41. Testosterone in prostate cancer: the Bethesda consensus.
Djavan B; Eastham J; Gomella L; Tombal B; Taneja S; Dianat SS; Kazzazi A; Shore N; Abrahamsson PA; Cheetham P; Moul J; Lepor H; Crawford ED
BJU Int; 2012 Aug; 110(3):344-52. PubMed ID: 22129242
[TBL] [Abstract][Full Text] [Related]
42. Risks and benefits of hormone replacement therapy in older men.
Pasqualotto FF; Lucon AM; Hallak J; Pasqualotto EB; Arap S
Rev Hosp Clin Fac Med Sao Paulo; 2004 Jan; 59(1):32-8. PubMed ID: 15029283
[TBL] [Abstract][Full Text] [Related]
43. Prostate cancer risk in testosterone-treated men.
Raynaud JP
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):261-6. PubMed ID: 17113983
[TBL] [Abstract][Full Text] [Related]
44. Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies.
Foley R; Marignol L; Keane JP; Lynch TH; Hollywood D
Prostate; 2011 Apr; 71(5):550-7. PubMed ID: 20945429
[TBL] [Abstract][Full Text] [Related]
45. The effect of androgen supplementation therapy on the prostate.
Kaufman JM
Aging Male; 2003 Sep; 6(3):166-74. PubMed ID: 14628497
[TBL] [Abstract][Full Text] [Related]
46. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management.
Kim HS; Freedland SJ
Curr Opin Support Palliat Care; 2010 Sep; 4(3):147-52. PubMed ID: 20592607
[TBL] [Abstract][Full Text] [Related]
47. Haematological actions of androgens.
Warren AM; Grossmann M
Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101653. PubMed ID: 35414435
[TBL] [Abstract][Full Text] [Related]
48. Management of the side effects of androgen deprivation therapy in men with prostate cancer.
Flaig TW; Glodé LM
Expert Opin Pharmacother; 2008 Nov; 9(16):2829-41. PubMed ID: 18937615
[TBL] [Abstract][Full Text] [Related]
49. The androgen receptor for the radiation oncologist.
Quero L; Rozet F; Beuzeboc P; Hennequin C
Cancer Radiother; 2015 May; 19(3):220-7. PubMed ID: 25921704
[TBL] [Abstract][Full Text] [Related]
50. Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression: Pro.
Morgentaler A
J Urol; 2016 Oct; 196(4):985-8. PubMed ID: 27449261
[No Abstract] [Full Text] [Related]
51. Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice.
Payne H; McMenemin R; Bahl A; Greene D; Staffurth J
Int J Clin Pract; 2019 Sep; 73(9):1-6. PubMed ID: 30414348
[TBL] [Abstract][Full Text] [Related]
52. Androgen deprivation therapy for prostate cancer: effects on hand function.
Soyupek F; Soyupek S; Perk H; Ozorak A
Urol Oncol; 2008; 26(2):141-6. PubMed ID: 18312932
[TBL] [Abstract][Full Text] [Related]
53. Testosterone and prostate cancer: revisiting old paradigms.
Isbarn H; Pinthus JH; Marks LS; Montorsi F; Morales A; Morgentaler A; Schulman C
Eur Urol; 2009 Jul; 56(1):48-56. PubMed ID: 19375844
[TBL] [Abstract][Full Text] [Related]
54. [Prostate carcinoma and testosterone: risks and controversies].
Rhoden EL; Averbeck MA
Arq Bras Endocrinol Metabol; 2009 Nov; 53(8):956-62. PubMed ID: 20126847
[TBL] [Abstract][Full Text] [Related]
55. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
56. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
[TBL] [Abstract][Full Text] [Related]
57. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
58. Effects of androgen deficiency and replacement on prostate zonal volumes.
Jin B; Conway AJ; Handelsman DJ
Clin Endocrinol (Oxf); 2001 Apr; 54(4):437-45. PubMed ID: 11318778
[TBL] [Abstract][Full Text] [Related]
59. The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer.
Shiota M; Fujimoto N; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Yokomizo A; Kajioka S; Uchiumi T; Eto M
J Urol; 2018 Mar; 199(3):734-740. PubMed ID: 28941922
[TBL] [Abstract][Full Text] [Related]
60. A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer.
Mohamad NV; Soelaiman IN; Chin KY
Endocr Metab Immune Disord Drug Targets; 2017 Nov; 17(4):276-284. PubMed ID: 28925899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
